30 closest matches · ranked by relevance
Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A
Primary: Area Under the Curve of Alfentanil Concentration vs. Time Extrapolated to Infinity — 58; 57; 55; 73 (hr*ng/ml/mg) — p=<.05
Healthy
Primary: DOBmax (Maximum Value of DOB) — 4.44; 3.49; 0.92 ratio
Human Gastrointestinal Physiology Data
Primary: Average Duodenal Fluid pH in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen — 5.12; 5.36 pH
Healthy
Primary: Plasma Cmax of Buprenorphine
Healthy
Primary: Group A - Efavirenz: Cmax — 771.0; 809.0 nmol/L
Chronic Liver Disease
Primary: Hepatic Decompensation Event — 324 number of events
Drug Interactions
Primary: AUC — 11900; 6830; 25500 h*ng/ml
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Local Drug Concentration in Gastrointestinal Tract
Primary: The AUC of Mesalamine in Plasma — 40.8; 57.6; 36.8; 7.9 nM*h
Drug Interactions
Primary: AUC of Ambrisentan — 3670; 3520; 2790 h*ng/ml
Drug Interactions
Primary: AUC of Bosentan — 9540; 5710; 5020 h*ng/ml
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Midazolam and 1-hydroxymidazolam — 22.0; 18.5; 9.92; 7.97 ng/mL
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Liver Transplant
Primary: Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation. — 33.3; 32.9…
Coronary Artery Disease
Primary: Platelet Reactivity Measured by VerifyNow — 16.9; 12.6 P2Y12 reaction units
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Patients With Compensated Liver Cirrhosis
Primary: CSPH (Clinically Significant Portal Hypertension) — 81.82 percentage of agreement
Liver Failure
Primary: Evaluation of Steady State Tacrolimus Trough Levels (C24). — 6.72 ng/mL
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration of BIA 9-1067 — 1108; 559 ng/mL
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) of BMS-790052 — 380; 382; 317; 698 nanograms/milliliter (ng/mL)
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MK-8189 — 5600; 4710 h*nmol/L
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam — 24.2; 50.7 Nanogram Hours per Milliliter…
Drug Interaction
Primary: AUC0-tlast of Midazolam — 34331.8; 28619.6 h*pg/ml
Healthy
Primary: Regional Collection of Metabolites and Gut Microbiota — 10 participants with sulfasalazine detected
Obesity · GERD
Primary: Pantoprazole Apparent Oral Clearance — 0.42; 0.29; 0.23 L/hr/kg
Nonalcoholic Steatohepatitis (NASH) · Primary Sclerosing Cholangitis (PSC)
Primary: Pharmacokinetic (PK) Parameter: AUClast of Cilofexor — 5381.0; 2972.6; 8223.7; 2756.7 h*ng/mL
Renal Transplant
Primary: Proportion of Patients Reaching Target Tacrolimus Levels (8-10 ng/mL) on Day 3 After Kidney Transplantation — 0.2; 0.14 proportion of participants — p=0.58
Genotyping Techniques
Primary: Percent Agreement — 100; 100; 100; 100 Percent Agreement
Depression
Primary: Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage — 469; 667; 706; 1002…